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Summary N-Benzyladriamycin-14-valerate (AD198) is a novel lipophilic anthracycline with greater in vivo
antitumour activity than doxorubicin (DOX) in experimental model systems. Using sensitive and progressively
DOX-resistant L1210 mouse leukaemia and B16-BL6 mouse melanoma lines, we have determined the cellular
pharmacokinetics and cytotoxic response in vitro and in vivo of AD 198. In the L1210 leukaemia model
following 3 h drug exposure in vitro, the IC,0 for AD 198 was approximately 0.35 1sgm1' for the
sensitive and 10-fold DOX resistant cells and 1.0 gsg ml-' for the 40-fold DOX resistant cells. A similar pattern
of cross-resistance to AD 198 was also observed with the B16-BL6 melanoma, with an IC50 for AD198 with
the sensitive and 10-fold DOX-resistant cells being similar, and about 2-fold higher with the 40-fold resistant
cells. In the L1210 leukaemia model, cellular pharmacokinetics of AD198 revealed the following: (a) accumula-
tion of AD198 was concentration but not time dependent, and cellular drug levels in the sensitive and resistant
sublines were similar when treated with equimolar concentrations; (b) retention of AD198 was 60% of the
initial drug uptake and, in cells treated with the IC,u of AD198, cellular levels in the 40-fold DOX-resistant
line were, as expected, 2-fold higher than in sensitive or 10-fold DOX-resistant cells; (c) in vitro biotransforma-
tion of AD 198 in the sensitive and resistant sublines was comparable. Studies in vivo with i.p. L1210
leukaemia (disseminating) and B16-BL6 melanoma (non-disseminating) tumour models evaluating therapeutic
efficacy of DOX vs AD198 in mice implanted with tumour i.p. on day 0 and treated i.p. on days 1-4
indicated: (a) DOX at 3 mg kg-' administered once daily on days 1 -4 resulted in a 55% ILS and 104% ILS
with parent-sensitive B16-BL6 melanoma and L1210 leukaemia models respectively; however, similar doses of
DOX in the resistant sublines were ineffective, with survival similar to the untreated control; (b) AD198 at
10-12.5mg kg-' day for 4 days was extremely effective in the sensitive L1210 (189% ILS), and similar to
DOX (61% ILS) in the sensitive B16-BL6; (c) AD 198 (10-12.5 mg kg-') was ineffective (survival similar to
untreated control) in the 10-and 40-fold DOX-resistant L1210 leukaemia and 40-fold DOX resistant B16-BL6
melanoma, but produced a 76% ILS in the 10-fold DOX resistant B16-BL6 melanoma. Results from this
study demonstrate: (a) in vitro AD 198 is capable of circumventing resistance to DOX in the cell lines studied;
(b) unlike DOX, cellular levels of AD198 are independent of the level of resistance; (c) in vitro cellular
pharmacokinetics and cytotoxicity studies of novel anthracyclines by themselves may be of limited value in
characterising therapeutic efficacy of agents for the treatment of DOX resistant tumours in vivo; and (d) the
characteristics of disseminating vs non-disseminating tumour model systems can influence outcome of in vivo
studies focused on circumvention of cellular resistance.
The potent antitumour antibiotic doxorubicin (DOX) con-
tinues in wide use in the chemotherapeutic management of a
broad spectrum of human malignancies (Blum & Carter,
1974; Young et al., 1981). However, the effectiveness of this
agent is often limited by tumour cell resistance which may be
of an 'intrinsic' or 'acquired' nature. Over the past several
years, the search for more efficacious analogues of DOX has
resulted in the development of a number of naturally occurr-
ing as well as semisynthetic anthracycline analogues. Based
on their differences from DOX in mechanistic and phar-
macokinetic properties, some of these products appear to
offer a possible advantage for use against resistant tumours
(Muggia et al., 1982; Israel et al., 1987a).
Separate from these drug development efforts, various
laboratories have been concerned with the identification of
the mechanisms by which tumour cells demonstrate resis-
tance to DOX and other anticancer drugs. Although 'intrin-
sic' resistance to DOX is poorly understood, studies with
murine and human models of acquired DOX resistance have
suggested reduced drug uptake and, more importantly,
reduced drug retention as major determinants of the
cytotoxic response (Skovsgaard, 1978; Inaba et al., 1979).
This alteration in drug accumulation, now recognised to be
associated with the multidrug resistant (MDR) phenotype, is
suggested to result from a P-glycoprotein-mediated active
efflux of cellular drug. This plasma membrane protein (M,
160,000-180,000) has also been demonstrated to serve as a
marker in cells resistant to DOX and other drugs of diverse
structure and mechanistic action (Gerlach et al., 1986b). Cer-
tain calcium modifiers, i.e. calcium antagonists and cal-
modulin inhibitors, are now known to be capable of
modulating the resistant phenotype, possibly by enhancing
cellular DOX levels (Tsuruo et al., 1982; Ganapathi &
Grabowski, 1983).
While cellular pharmacology studies with DOX have pro-
vided some basis to demonstrate the relationship of intracel-
lular drug levels to cytotoxicity, it has also been noted that
the magnitude of the reduction of cellular drug accumulation
in resistant cells frequently does not correlate with the exp-
ression of resistance (Ganapathi & Grabowski, 1988;
Ganapathi et al., 1986; Louie et al., 1986). An important
finding which appears not to substantiate reduced anthracyc-
line accumulation as the major determinant of cytotoxicity is
that certain lipophilic anthracyclines are accumulated to a
similar extent in sensitive and resistant murine P388
leukaemia cells (Ganapathi et al., 1984, 1985), and yet show
no significant capacity to circumvent DOX resistance to this
tumour in vivo (Johnson et al., 1978; Chandrasekaran et al.,
1987). Although incompletely understood at the present time,
the limited in vivo activity of these lipophilic anthracyclines
may possibly relate to the artificially high levels of DOX
resistance (100-fold or greater) conferred upon these model
systems.
Recently, N-benzyladriamycin-14-valerate (AD 198) has
been described as a newer lipophilic anthracycline analogue
therapeutically superior to DOX in murine tumour systems
and with novel biochemical and pharmacological properties
(Israel et al., 1985, 1987a, 1989; Israel & Seshadri, 1986;
Traganos et al., 1985; Bodley et al., 1989). Of particular
interest are the findings that AD 198 shows similar in vitro
Correspondence: R. Ganapathi.
Received 11 April 1989; and in revised form 19 July 1989.
%17" The Macmillan Press Ltd., 1989 Br. J. Cancer (1989), 60, 819-826820 R. GANAPATHI et al.
growth-inhibitory and anticlonogenic activity against
biochemically different resistant sublines as compared to the
parent sensitive cell lines, suggesting that this compound may
possess an ability to circumvent resistance even due to
differing mechanisms (Maniar et al., 1988; Sweatman et al.,
1988). Based on these findings, the present study with
AD 198 was undertaken to characterise the relationship
between cellular drug levels and antitumour activity in vitro
and in vivo utilising two recently described progressively
DOX-resistant (5-40-fold) murine tumours, namely L1210
leukaemia (Ganapathi & Grabowski, 1988) and B16-BL6
melanoma (Ganapathi et al., 1987, 1988).
Materials and methods
Drug materials
AD 198 and N-benzyladriamycin (AD 288) were prepared as
previously described (Israel & Seshadri, 1986). N-
benzyladriamycinol was obtained from AD 288 by reduction
with sodium cyanoborohydride. Materials used in this study
for cell treatments, in vivo antitumour assays, and as
analytical reference standards were of >98% purity, as
determined by HPLC. Diluent 12 (equal volumes of
Cremaphor EL polyethoxylated castor oil and absolute
ethanol) was obtained from the Pharmaceuticals Resources
Branch, Division of Cancer Treatment, National Cancer Ins-
titute, Bethesda, MD.
Tumour cell lines
The sensitive and progressively DOX-resistant sublines of
murine L1210 leukaemia and B16-BL6 mouse melanoma
have been previously described (Ganapathi et al., 1987, 1988;
Ganapathi & Grabowski, 1988). Briefly, these sublines were
developed by adapting cells to grow continuously in the
presence of 0.05jig ml-' and 0.25 jg ml-' DOX and are
identified as L1210/DOXO.05, L1210/DOXO.25, B16-BL6/
DOXO.05 and B16-BL6/DOXO.25. Based on in vitro cytotox-
icity studies using a soft agar colony formation assay, the
sublines selected in 0.05 jig ml-' DOX and 0.25 jig ml-'
DOX were 10-fold and 40-fold DOX resistant, respectively,
compared to the corresponding parent sensitive cells (Li210/
S or B16-BL6/S).
Parent sensitive (L1210/S) and DOX-resistant sublines
(L1210/DOXO.05 and L1210/DOXO.25) of L1210 leukaemia
were maintained in vitro as suspension cultures using RPMI
1640 medium, supplemented with 25 mM HEPES buffer,
2 mM L-glutamine, 10% fetal bovine serum (FBS), and 10 jiM
2-mercaptoethanol. The doubling time in vitro of the L1210
sensitive and DOX-resistant sublines was 10.7 ± 0.1 h (Gana-
pathi & Grabowski, 1988). The parent-sensitive (B16-BL6/S)
and DOX-resistant sublines (B16-BL6/DOXO.05 and B16-
BL6/DOXO.25) of B16-BL6 melanoma were maintained in
vitro as monolayer cultures using Eagle's minimum essential
medium with Hank's salts, supplemented with non-essential
amino acids, sodium pyruvate, vitamins, 2mM L-glutamine
and 5% FBS. Cells were subcultured weekly using 0.25%
trypsin, 0.02% EDTA. The doubling time in vitro of the
sensitive and progressively DOX-resistant sublines of B16-
BL6 melanoma was approximately 16-18 h (Ganapathi et
al., 1987, 1988). All in vitro cultures were maintained at 37%
in a humidified 5% CO2 plus 95% air atmosphere. Media
and supplements were obtained from M.A. Bioproducts,
(Walkersville, MD, USA) and FBS was from Hyclone
Laboratories (Logan, UT, USA).
AD 198 and AD 288 in vitro cytotoxicity
Cytotoxicity studies were carried out using a soft agar
colony-forming assay (Ganapathi & Grabowski, 1988). Log-
phase cultures of parent sensitive (Li210/S), 10-fold DOX-
resistant (L1210/DOXO.05) and 40-fold DOX-resistant
(L1210/DOXO.25) L1210 mouse leukaemia cells at a density
of 1 x 106 cells ml1- in RPMI 1640, supplemented with 10%
FBS, were treated with 0.1-2.5 tLgml' AD 198 or AD 288
for 3 h at 37°C in a humidified 5% CO2 plus 95% air
atmosphere. Cells were centrifuged (80g) and washed twice
in drug-free RPMI 1640 supplemented with 10% FBS. Con-
trol and treated cells were plated in triplicate at a density of
5 x 103 cells per 35 x 10 mm Petri dish in RPMI 1640 supple-
mented with 20% FBS and 10gM 2-mercaptoethanol. Fol-
lowing incubation at 37°C in a humidified 5% CO2 plus 95%
air atmosphere for 96 h, colonies (>50 cells) in untreated
control and treated plates were counted in an Omnicon
Feature Analysis System II (Bausch & Lomb, Rochester,
New York). Cytotoxicity in sensitive (B16-BL6/S) and pro-
gressively DOX-resistant sublines (B16-BL6/DOXO.05 and
B16-BL6/DOXO.25) of B16-BL6 melanoma was determined
by treating log-phase monolayer cultures in vitro with
0.1-2.5fg ml-' AD 198 for 1 h at 37°C in a humidified 5%
CO2 plus 95% air atmosphere. Cultures were subsequently
washed twice with drug-free medium and incubated for an
additional 72 h with fresh medium. Cell counts, following
trypsinisation in untreated control and treated cultures, were
determined by means of a Coulter counter.
Cellular accumulation ofAD 198 in vitro
In one set of experiments, log-phase cultures of parent sen-
sitive (L1210/S) and progressively DOX-resistant (L1210/
DOXO.05 and L1210/DOXO.25) L1210 mouse leukaemia cells
at a density of 1 x 106 cells ml-l in RPMI 1640 supplemented
with 10% FBS were treated with 0.25jig ml-', 0.5jig ml-'
and 1.0 jLg ml-' AD 198 at 37°C in a humidified 5% CO2
plus 95% air atmosphere. Duplicate aliquots (1 x 106 cells
per sample), removed at the end of 1 h of treatment, were
centrifuged (100g) and washed twice with 7 ml of ice-cold
0.85% sodium chloride solution. The cells pellet following
the final wash was resuspended in 50% ethanol, 0.3N hydro-
chloric acid, mixed thoroughly in a vortex mixer and centri-
fuged (700g), and the total anthracycline content in the
supernatant was determined fluorimetrically in an Aminco-
Bowman spectrophotofluorometer (American Instruments
Co., Silver Springs, MD) at excitation and emission
wavelengths of 470 nm and 585 nm, respectively (Ganapathi
et al., 1984, 1985). Standard curves of AD 198 prepared in
50% ethanol, 0.3N hydrochloric acid were used for computa-
tion of total anthracycline content, which was expressed as
nmol AD 198-equivalents per 106 cells.
Cellular anthracycline accumulation was also determined
by HPLC/flow fluorescence analysis following 3 h drug
exposure as part of a detailed study on drug uptake, reten-
tion and biotransformation. As above, L1210/S, L1210/
DOXO.05 and L1210/DOXO.25 cells were exposed to AD 198
at their IC50 concentrations (0.5, 0.5, 1.0jLg ml-', respec-
tively). After 3 h incubation, the cells were harvested and
washed twice with ice-cold 0.85% sodium chloride solution,
and the resulting cell pellets were sonicated in cold 0.85%
sodium chloride solution (2 ml). For analysis, samples, in
duplicate, were diluted with Tris buffer (0.05 M, pH 8.5, 3 ml)
and subjected to organic extraction (ethyl acetate: 1-
propanol, 9:1 by volume, 2 x 8 ml). The two organic extracts
for each sample were combined and evaporated to dryness
(37°C) under a stream of dry nitrogen gas. Dried samples
were stored at -70°C pending analysis. The efficiency of
extraction was monitored by reference to standard curves
derived from the extraction of known quantities of authentic
standards added to sonicates of untreated cells.
Samples were reconstituted in methanol (60-100jil) before
assay. HPLC separation conditions were as follows: reverse-
phase 10ji phenyl-RADIALPAK radial compression column
(Waters Associates, Milford, MA); initial mobile phase con-
ditions, 25% acetonitrile: 75% ammonium formate buffer,
0.05 M, pH 4.0; final conditions, 75% acetonitrile: 25%
buffer, linear gradient over 20 min; flow rate 2.5 ml min-'.
Column eluate was monitored by flow fluorimetry (Model FS
970, Schoeffel Instruments, Ramsay, NJ), 482 nm excitation
wavelength, 550 nm emission filter. Fluorescent signals wereCROSS RESISTANCE TO AD 198 821
identified and quantified by reference to standard curves
constructed from authentic reference samples. Results of
HPLC fluorimetric assays are expressed on the basis of 106
viable cells. The in vitro and in vivo biotransformation pro-
ducts of AD 198 have been rigidly characterised in previous
studies (Israel & Seshadri, 1986; Israel et al., 1987a, b, 1989).
Cellular retention andbiotransformation ofAD 198 in vitro
Parental sensitive (L1210/S) and DOX-resistant cells (L1210/
DOXO.05 and L1210/DOXO.25) in RPMI 1640 supplemented
with 10% FBS were pretreated with the IC50 of AD 198
(0.5 Lg ml ' for L1210/S and L1210/DOXO.05, and
1.0pgml-' for L1210/DOXO.25) for 3h at 37°C in a
humidified 5% CO2 plus 95% air atmosphere. Cells were
then centrifuged, resuspended in drug-free medium (RPMI
1640 supplemented with 10% FBS) and incubated at 37°C.
Aliquots of cells (5 x 106 cells per sample) from replicate
experiments retrieved at the end of the 3 h accumulation
phase, and subsequently at 1, 2, 4, 8 and 24 h during the
retention phase, were centrifuged (100g) and washed three
times in ice-cold 0.85% sodium chloride. Cell pellets were
sonicated and extracted, and the levels of AD 198 and
metabolites were quantified by HPLC/flow fluorescence
detection. Total cellular anthracycline content at each time
point was computed by summing the amounts of the individ-
ual anthracycline species present; negligible amounts of drug
were lost in the wash.
Antitumour activity ofAD 198 in vivo
Female DBA/2n or CD2F1 mice for L1210 mouse leukaemia
and male C57BI/6NCr mice for B16-BL6 mouse melanoma
were used for in vivo studies. Mice were obtained from the
Animal Genetics and Production Branch, Frederick Cancer
Research Facility, National Cancer Institute, Fort Detrick,
Maryland. Tumour inoculum for L1210 mouse leukaemia
and B16-BL6 mouse melanoma was 105 cells and 106 cells,
respectively. Cells from log-phase cultures of parental sen-
sitive and DOX-resistant sublines as a single cell suspension
(viability >95% based on trypan blue dye exclusion) in
sterile 0.9% sodium chloride solution were injected i.p. into
mice in groups of six to eight matched for age, weight and
sex (day 0). Drugs were formulated for assay in 20% Diluent
12, 80% saline. Groups of mice were subsequently treated
i.p. once daily on days 1-4 with the following: (a) vehicle
alone (controls); (b) 3 mg kg-' DOX; or (c) 10 mg kg-' or
12.5mgkg-' of AD 198. The doses of DOX and AD198
used in these studies were based on the optimal doses for
these compounds determined in earlier studies (Israel et al.,
1975, 1985, 1986, 1987a). Each experiment was replicated at
least twice for the determination of mean survival time and
median per cent increase in lifespan (% ILS) of treated
animals relative to untreated controls.
Results
Cytotoxic effects in vitro of AD 198 following drug treat-
ment for 3 h in sensitive and progressively DOX-resistant
sublines of L1210 mouse leukaemia are outlined in Figure 1.
The data demonstrate that >90% cell kill can be achieved
over the range of concentrations evaluated. Further, based
on regression analysis of the dose-response curves, the IC50
values for AD 198 in the L1210/S and L1210/DOXO.05 cells
were not significantly different (approximately 0.35 tgml-').
However, the IC50 ofAD 198 for the L1210/DOXO.25 subline
(1.0 Ilg ml-1') was significantly different (P <0.05). The
cytotoxic effects of AD 198 in sensitive and progressively
DOX resistant B16-BL6 cells (Figure 2) followed a similar
trend, and the IC5o was found to be 0.3 1ig ml-' AD 198 for
the B16-BL6/S and B16-BL6/DOXO.05 cells, and 1.0fig ml-'
AD 198 for the B16-BL6/DOXO.25 cells.
Since it is widely accepted that reduced cellular drug
uptake and/or retention of anthracyclines is a major
mechanism involved in the expression of the MDR
phenotype (Inaba et al., 1979; Gerlach et al., 1986b), we
evaluated both uptake and retention of AD 198 in sensitive
and progressively DOX-resistant L1210 mouse leukaemia
cells. In a preliminary study, total anthracycline cellular
accumulation was determined spectrophotometrically after 1
and 3 h of continuous exposure to AD 198 at three different
concentrations (Table I). From results outlined in Table I, it
is evident that drug accumulation is dependent on extracel-
lular concentration but independent of time of exposure (1 h
vs 3 h). Further, unlike results with DOX where differences
were seen (Ganapathi & Grabowski, 1988), accumulation of
AD 198 was comparable in the sensitive and resistant sub-
lines. In another study, HPLC analytical data were used to
determine intracellular anthracycline content after 3 h
exposure to the ICo concentrations of AD 198. Data pro-
vided in Table II additionally document the extent of drug
uptake by cells exposed to AD 198. In this, as in related
studies (Israel et al., 1987b, 1989), AD 198 was found to
accumulate rapidly and extensively in cells, achieving a
cell:medium partition ratio of 7:3.
The putative role of P-glycoprotein, which is overexpressed
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Figure 1 Cytotoxicity
(AD 198) in sensitive
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Figure 2 Cytotoxicity of N-benzyladriamycin-14-valerate
(AD 198) in sensitive (-, B16-BL6/S) and progressively doxo-
rubicin-resistant (---, B16-BL6/DOX 0.05; . B16-BL6/
DOX0.25) B16-BL6 mouse melanoma cells. Bars are s.e.
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Table I Cellular anthracycline accumulation in sensitive and progressively doxorubicin-
resistant LI210 mouse leukaemia cells following continous exposure to AD 198
Applied
concentration AD 198a Time L1210/S L1210/DOX0.05 L1210/DOX0.25
0.25 fig ml- I h 0.17lb 0.166b 0.163b
3 h 0.183 0.184 0.182
0.5 lag ml' 1 h 0.371 0.362 0.359
3 h 0.411 0.406 0.415
1.0jig ml-' 1 h 0.737 0.744 0.709
3h 0.794 0.801 0.775
-L1210/S, L1210/DOXO.05 and L1210/DOXO.25 cells were treated withvariousconcent-
rations ofAD 198 and drug content determined fluorimetrically as outlined in Materials
andmethods. Drugconcentrationsindicated areequivalent to0.348,0.697and 1.393 nmol
AD 198 per ml, respectively, "Total cellular anthracycline content expressed as nmol
AD 198-equivalent per 106cells. Dataaremeanvalues from atleastduplicateexperiments
and the coefficient of variation was <10%.
Table II Drug accumulation, retention, and biotransformation in parent sensitive and progressively
doxorubicin-resistant L1210 mouse leukaemia cells exposed to AD 198a
Time L1210/S L1210/DOX0.05 L1210/DOX0.25
AD 198 AD 288 Total AD 198 AD 288 Total AD 198 AD 288 Total
anthracycline anthracycline anthracycline
conten( conten( conten(
Accumulationb
3 h 0.384 0.018 0.492 (71%)d 0.357 0.114 0.471 (68%)d 0.807 0.240 1.047 (75%)d
Retentione
I h 0.212 0.088 0.300 (61%)f 0.171 0.082 0.253 (54%)f 0.448 0.211 0.660 (63%)f
2 h 0.224 0.117 0.343 (70%) 0.181 0.104 0.288 (61%) 0.448 0.228 0.684(65%)
4 h 0.199 0.125 0.324(66%) 0.154 0.120 0.286(61%) 0.386 0.258 0.644(61%)
8 h 0.171 0.150 0.327(66%) 0.131 0.141 0.276(58%) 0.337 0.313 0.666(64%)
24h 0.067 0.205 0.272(55%) 0.042 0.137 0.181 (38%) 0.159 0.303 0.479(46%)
aCellular AD 198, AD 288, andAD 298content, asdetermined byHPLC/flowfluorescenceassay,expressed
asnmolper 106cells. Dataaremeanvaluesfrom atleastduplicateexperiments, with acoefficientofvariation
of <10%. bL1210/S and L1210/DOXO.05 cells were treated with 0.5jigml-I AD 198 (equivalent to 0.697
nmol per 106 cells per ml) and L1210/DOXO.25 cells were treated with 1.0figml'l AD 198 (equivalent to
1.393 nmol per 106 cells per ml) for 3 h at 37°C.cParent drug plus biotransformation products AD 288 and
AD 298; no other anthracycline materials detected. dNumbers in parentheses, for the accumulation phase,
represent the per cent of the applied drug concentration partitioned into the cells at the end of 3 h of
continuous drug exposure. eTime following the placement of 3-h pretreated cells in drug-free media.
'Numbers inparenthesis, fortheretentionstudies, represent thepercentoftotalanthracycline retained inthe
cells at the indicated times relative to the amount present after the 3-h accumulation phase.
in the DOX-resistant L1210 cells (Ganapathi et al., 1989), is
suggested to involve active drug efflux (Gerlach et al., 1986b).
Accordingly, in order to correlate cytotoxic effects with drug
retention, cells were pretreated with the experimentally deter-
mined IC50 concentrations of AD198 and retention was deter-
mined over 24 h. Retention data for AD 198, provided in
Table II, indicate that approximately 40% of presumably
loosely bound drug is lost within the first hour when
pretreated cells are placed in drug-free medium. Some re-
equilibration of drug occurred for a period of time up to 2 h,
and thereafter, for at least 6 h, intracellular drug levels
remained essentially unchanged. Significant levels of drug
were still present within the cells at 24 h. It is of interest to
note that at the IC50 of AD198 for L1210/DOXO.25 cells, as
expected from the applied concentration, both initial uptake
and subsequent retention of cellular AD 198 levels were ap-
proximately 2-fold greater than for the L1210/S and L1210/
DOXO.05 cells. Retention of AD198, expressed as a percent-
age of the initial drug uptake, was essentially similar in the
sensitive and 40-fold resistant sublines, whereas a somewhat
lower level of drug was achieved in the L1210/DOXO.05
subline.
Results from studies on AD 198 biotransformation in
L1210/S, L1210/DOXO.05, and L1210/DOX0.25 cells during
uptake and retention are included in Table II. The data
indicate that during the accumulation phase AD 198 is the
predominant species, with AD 288 accounting for approxi-
mately 25% of the total drug in each cell line. Although
AD 198 remains the predominant species during the early
phase of the retention (up to 4 h), levels of AD 288 continue
to increase and by 24 h exceed those of parent drug. While
intracellular levels of AD 198 were similar in the sensitive
and L1210/DOX0.05 resistant subline in the L1210/DOXO.25
cells treated with a 2-fold higher drug concentration, cellular
levels of AD 198 and AD 288 were, as expected, correspond-
ingly greater. Levels of AD 298, occasionally detectable,
represented at most only 1-3% of the total anthracycline
content.
Cytotoxic effects in vitro of AD288 following treatment
for 3 h in sensitive and progressively DOX-resistant L1210
mouse leukaemia cells are outlined in Figure 3. In contrast to
AD 198, cross-resistance to AD 288 was observed (IC50 of
AD 288 in L1210/S, L1210/DOX0.05 and L1210/DOX0.25
cells, 0.25, 0.5, and 1.0jigml-', respectively).
To determine if in vitro results have validity in an in vivo
setting, the antitumour efficacy ofAD 198 compared to DOX
was evaluated in mice implanted with the sensitive and pro-
gressively DOX-resistant tumours. Results of studies with
sensitive and progressively DOX-resistant L1210 mouse
leukaemia are outlined in Figure 4. In the L1210/S line,
DOX was effective, and survival was more than doubled
(104% ILS) compared to the untreated control; approxi-
mately 10% long-term survivors (>60 days) were observed
in replicate experiments. As previously noted with this
tumour (Israel & Seshadri, 1985), AD 198 was more effective
than DOX; in these studies a % ILS of 189 was obtained,CROSS RESISTANCE TO AD 198 823
vitro, parental L1210/S and B16-BL6/S cells and their 10-fold
DOX-resistant sublines are equally sensitive to AD 198, while
their counterpart 40-fold DOX-resistant lines are only 2-fold
resistant to the analogue (Figure 1 and Figure 2). Following
exposure to AD 198, cells rapidly and extensively take up
L1210/S (parent-sensitive)
U)
o
Ln
20
0 AD 288 (,g ml-')
Figure 3 Cytotoxicity of N-benzyladriamycin (AD 288) in sen-
sitive (-, L1210/S) and progressively doxorubicin-resistant (---,
L1210/DOX 0.05; ..... L1210/DOX 0.25) L1210 mouse leukemia
cells. Each point is the mean value of replicate determinations
from at least duplicate experiments, with a coefficient of variation
of <10%.
:.....
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Dox3mgkg
AD 19810 mg kg
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7.8 ± 0.2
15.8 ± 1.0 104
22.4 ± 0.6 189
L1210/Dox 0.05 (10-fold Dox-resistant)
and in replicate experiments there were 40% long-term sur-
vivors (>60 days). In contrast to the results with L1210/S,
DOX was ineffective in the L1210/DOXO.05 and L1210/
DOXO.25 cells (% ILS only 22-24). Despite the superior
therapeutic efficacy of AD 198 vs DOX in the L1210/S
system, AD 198 proved ineffective in prolonging survival in
both the L1210/DOXO.05 and L1210/DOX0.25 (mean sur-
vival time similar to the untreated control).
Similar studies comparing the therapeutic efficacy of DOX
and AD 198 in sensitive and DOX-resistant B16-BL6 cells
are shown in Figure 5. Therapeutic efficacy of DOX in the
B16-BL6/S cells was apparent (55% ILS). However, in con-
trast to the results with L1210/S (Figure 4), AD 198 was
found to be only equiactive with DOX in the B16-BL6/S
model (61% ILS and no long-term survivors). Similar to
results with the DOX-resistant L1210 sublines, DOX was
ineffective against the B16-BL6/DOXO.05 and B16-BL6/
DOXO.25 tumour systems in vivo. In contrast to the results
with the DOX-resistant-L1210 cells, AD 198 retained
effectiveness (76% ILS) in the B16-BL6/DOXO.05 model at a
level essentially equivalent to that in the parent sensitive
B16-BL6/S system. However, with the B16/BL6/DOXO.25
cells, no therapeutic efficacy of AD 198 was present.
Discussion
Tumour cell resistance and, in particular, the multidrug resis-
tant phenotype have received considerable attention at the
experimental and clinical level (Gerlach et al., 1986b). Since
the identification of P-glycoprotein in MDR cells, and its
homology to bacterial active transport proteins, resistance to
drugs with diverse mechanisms of action has been attributed
to an active drug efflux process (Gerlach et al., 1986a).
Although this mechanism has gained considerable popularity,
at least with anthracyclines, there is actually limited correla-
tion between alteration in drug uptake/efflux and expression
of resistance (Ganapathi et al., 1986; Louie et al., 1986;
Ganapathi & Grabowski, 1988). The present investigation
was undertaken to explore the relationship between cytotox-
icity and drug accumulation/retention with a novel lipophilic
DOX analogue, which in other in vitro studies (Maniar et al.,
1988; Sweatman et al., 1988) has demonstrated an ability to
circumvent resistance in MDR cells.
Using two sets of parent sensitive and progressively DOX-
resistant murine cell lines, the present study shows that, in
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tumour cells and treated i.p. with vehicle alone (control), DOX or
AD 198. Data presented are the composite from two separate
experiments with at least six mice per group.
100
- 75
4-
C
0
0
50
L-
° 25
0
0
v824 R. GANAPATHI et al.
drug, achieving a 7:3 partitioning ratio between cells and
medium at equilibrium (Tables I and II). This is in marked
contrast to DOX which, in other studies, accumulates
gradually and, at equilibrium, achieves a cell:media partition-
ing ratio of only 1:11 following cellular drug exposure
B16-BL6/S (parent-sensitive)
0 5 10 15 20 25 30 35
Days
Control
Dox3mgkg 1
--- AD 198 12.5 mg kg
40 45
MST + s.e.
(days) % ILS
15.0 + 0.4
23.2 + 3.0 55
1 24.2± 1.0 61
B16-BL6/Dox 0.05 (10-fold Dox-resistant)
0 5 10 15 20 25 30 35 40 45
Days
MST + s.e.
(days) % ILS
Control
Dox3mg kg 1
--- AD 198 12.5 mg kg
13.9 ± 0.2
15.7 +0.8 13
24.4 + 2.2 76
B1 6-BL6/Dox 0.25 (40-fold Dox-resistant)
.71
30 35 40 45
Days
Control
Dox 3 mg kg
1
--- AD 198 12.5 mg kg
MST + s.e.
(days) % ILS
18.9 ± 0.7
22.7 + 1.4 20
1 24.2 ± 2.2 28
Figure 5 Effect of DOX or AD 198 on survival of mice
implanted with B16-BL6/S (sensitive) B16-BL6/DOXO.05 (10-fold
DOX-resistant) and B16-BL6/DOXO.25 (40-fold DOX-resistant)
B16-BL6 mouse melanoma cells. Mice were implanted i.p. with
106 tumour cells and treated i.p. with vehicle alone (control),
DOX or AD 198. Data presented are the composite from two
separate experiments with at least six mice per group.
(Traganos et al., 1985; Israel et al., 1987b, 1989). Further-
more, with AD 198, no significant difference is seen in drug
accumulation between parent sensitive and 10-fold DOX-
resistant L1210 cells exposed to their IC_, concentrations;
40-fold DOX-resistant L1210 cells, with an ICotwice that of
the sensitive and 10-fold DOX-resistant cells, correspondingly
accumulate 2-fold higher drug levels under similar condi-
tions.
Intracellular drug persists at high levels in cells which are
pretreated with AD 198 at the IC50 concentration and then
transferred to drug-free medium. While drug efflux was per-
haps somewhat greater in the 10-fold DOX-resistant L1210
cells, no major differences were apparent with respect to the
extent ofdrug retention in L1210/S compared to the progres-
sively DOX-resistant sublines with all three cell lines retain-
ing for over 8 h about 60% of the 3 h accumulated drug
levels (Table II). Also, no significant differences in cellular
drug biotransformation were seen in L1210/S vs progressively
DOX-resistant cells (Table II).
Like many other MDR model systems (Gerlach et al.,
1986b), the DOX-resistant sublines of L1210 leukaemia
(Ganapathi et al., 1989) and B16-BL6 melanoma (Ganapathi
et al., 1987) overexpress P-glycoprotein. However, overall,
the results presented here indicate that reduced drug uptake
and/or retention in vitro is not the determinant of AD 198
cytotoxicity in the resistant cell lines studied. A better corre-
lation exists with cellular drug accumulation required to
achieve equivalent cytotoxicity. In this same vein, results
from earlier studies with DOX in the progressively DOX-
resistant L1210 and B16-BL6 cells also indicated that, for
equivalent cytotoxicity, the resistant cells accumulated and
retained significantly higher drug levels (Ganapathi &
Grabowski, 1988; Ganapathi et al., 1987, 1988).
The present results suggest that the sensitivity of the cel-
lular target responsible for anthracycline cytotoxicity is
altered with increasing resistance. In these model systems, no
alterations in glutathione metabolism have been observed
(unpublished observations), suggesting expression of resis-
tance by alternate mechanisms. One putative target for
DOX-induced cytotoxicity involves damage to DNA through
drug interference of DNA topoisomerase II activity (Tewey
et al., 1984; Silber et al., 1987). Comparative studies in L1210
leukaemia indicate that topoismerase II-mediated DNA
cleavage by nuclear extracts is significantly attenuated in the
DOX-resistant sublines vs the parent sensitive cells
(Ganapathi et al., 1989). Although AD 198 and its principal
biotransformation product AD 288 cause significant levels of
protein-associated DNA strand breaks on alkaline elution
assay (Potmesil et al., 1986), neither of these agents can be
shown to inhibit isolated mammalian DNA topoisomerase II
(Bodley et al., 1989). Thus, AD 198 and intracellularly
derived AD 288 may interact with DNA topoisomerase II in
a manner quite different from that of DOX, and this
difference could be a basis of enhanced sensitivity to AD 198
in vitro in DOX-resistant cells.
Based on studies suggesting the role of reduced drug
uptake and/or retention as a mechanism of resistance, the
calcium modifiers (i.e. calcium blockers and calmodulin
inhibitors) are suggested to enhance cytotoxicity in resistant
cells by increasing drug retention (Tsuruo et al., 1982;
Ganapathi & Grabowski, 1983). However, in studies with the
calmodulin inhibitor trifluoperazine (TFP), this agent was
previously shown to be ineffective in modulating cellular drug
levels and/or cytotoxicity of lipophilic anthracyclines
(Ganapathi et al., 1984, 1985). Similarly, in the present study,
neither the accumulation nor the cytotoxicity ofAD 198 were
altered by TFP in the sensitive or DOX-resistant sublines.
These results with TFP are distinct from those observed with
DOX (Ganapathi & Grabowski, 1988), and suggest that the
role of TFP in modulating cytotoxicity of DOX vs AD 198
may possibly relate to differences in mechanism of action
between these agents. Overall, the present results on cellular
drug levels and cytotoxicity of AD 198, and the effects of
TFP in progressively DOX-resistant cells (10-40-fold) are in
agreement with previous studies on lipophilic anthracyclines
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in > 100 fold DOX-resistant tumour cells (Ganapathi et al.,
1984, 1985).
Consistent with earlier in vivo observations (Israel et al.,
1987a; Israel & Seshadri, 1986), AD 198 was again found to
be therapeutically superior to DOX in the L1210/S system
(Figure 4). However, despite the near or total absence of
cross-resistance to DOX seen in vitro, no therapeutic benefit
was afforded with AD 198 against L1210/DOX0.05 and
L1210/DOXO.25 in vivo on the daily x 4 treatment schedule.
Drug metabolism might be responsible for the treatment
failure seen with AD 198 against these DOX-resistant L1210
sublines. Cytotoxicity with AD 198 is considered to be due to
the effects of parent drug and its mechanistically different
biotransformation product AD 288, which, together, persist
at high levels within the cells. The conversion ofAD 198 into
its principal metabolite AD 288 occurs more rapidly in vivo
than in vitro. Although AD 288 is more cytotoxic than
AD 198 vs cultured L1210/S cells (ICm 0.25jigml1'; Figure 3
vs Figure 1), when administered to tumour-bearing animals
this agent is effective at a level only equivalent to that of
DOX (Israel et al., 1987a). Biochemically, AD 288 behaves
more like DOX than like AD 198 in its interactions with
DNA and it fails to show the membrane-active properites
seen with AD 198 (Israel et al., 1987a). In the present study,
against L1210/DOXO.05 and L1210/DOXO.25 cells, the ICm in vitro of AD 288 was 2- and 4-fold greater, respectively,
than against L1210/S cells (Figure 3), and this may explain
the absence of antitumour activity in vivo against the DOX-
resistant L1210 sublines.
Studies with the highly disseminated L1210/S and progres-
sively DOX-resistant L1210 sublines point to the need to
evaluate solid tumour models in vivo to demonstrate poten-
tial circumvention of resistance by drugs, and in this regard,
antitumour activity in vivo of AD 198 with the B16-BL6/S
melanoma and its progressively DOX-resistant sublines
becomes more informative. AD 198 and DOX are equally
effective against B16-BL6/S in vivo (Figure 5); the lesser
response of these drugs against this tumour compared to
L1210/S suggests possible differences in the intrinsic sen-
sitivity of the tumour cells to these agents. However, with the
B16-BL6 model system, the activity of AD 198 is retained
against the 10-fold DOX-resistant tumour, while DOX is
ineffective. Thus, the sensitivity of AD 198 vs B16-BL6/
DOX0.05 seen in vitro is correspondingly achieved in vivo. In
the 40-fold DOX-resistant subline in vivo with AD 198
activity is abolished. Since only a 2-fold level of resistance is
seen in vitro with AD 198 in the B16-BL6/DOX0.25 (40-fold
DOX-resistant) compared to parent B16-BL6/S cells, loss of
in vivo activity suggests, at least for this system, that a 2-fold
difference of IC_0 in vitro may be capable of negating the
therapeutic activity of an otherwise superior DOX analogue.
In summary, results from this study demonstratre that in
progressively DOX-resistant (<40-fold) model systems, little
(<2-fold) or no cross-resistance in vitro to AD 198 is
observed. Although, unlike DOX (Ganapathi & Grabowski,
1988), the cellular uptake and/or retention of AD 198 is not
dependent on the level of resistance, for equivalent cytotox-
icity the 40-fold resistant tumours tend to accumulate and
retain significantly higher levels of drug. Finally, the limited
therapeutic efficacy of AD 198 against DOX-resistant
tumours suggests that in vitro cellular pharmacokinetics and
cytotoxicity studies of novel anthracyclines by themselves
may be of limited value in characterising therapeutic efficacy
of these agents for the treatment of DOX-resistant tumours
in vivo. However, the results presented provide an excellent
model for further studies to identify the factors in MDR cells
which result in resistance to chemotherapy in vitro and in
vivo.
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